Saint Snt denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for saint snt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied SAINT TMS as Not FDA-Approved — and How to Appeal

SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) is an accelerated, individually targeted rTMS protocol for treatment-resistant major depressive disorder (MDD). BCBS's not-FDA-approved denial reflects a question about the regulatory status of the specific device and protocol combination being billed. TMS devices have received FDA clearance for MDD, but the FDA clearance pathway (510(k) or De Novo) and exact labeled indications differ by device and software version. A "not FDA-approved" denial often means the claim was submitted under a billing code or device that BCBS's system did not recognize as carrying the relevant clearance.

This denial is highly specific and frequently correctable with documentation.

### Why This Is Appealable

If the device used for SAINT has FDA 510(k) clearance or De Novo authorization for the intended use, the denial is factually incorrect and can be overturned with documentation from the treating facility showing the device's FDA clearance status. Verify the device's clearance status directly on the FDA's 510(k) database (accessdata.fda.gov) and include the relevant clearance documents in your appeal.

### Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): You are entitled to a full-and-fair review. Non-urgent: plan must respond within 60 days. Expedited track for urgent cases.
• External review (ACA §2719): If the internal appeal fails, request independent external review. Window is approximately four months from the final denial — confirm the exact date on your letter.
• MHPAEA parity: If BCBS applies a stricter FDA-approval standard to mental health devices than to comparable physical-health devices, raise a parity challenge explicitly.

### Appeal Process and Timeline

1. Contact the treating facility immediately to confirm which specific TMS device and software version was used. 2. Look up that device's FDA clearance on the FDA 510(k) database; print the clearance summary. 3. Confirm that the procedure was billed under the correct CPT code for the device and protocol used. 4. File a written internal appeal with the FDA clearance documentation attached. 5. If upheld, file external review.

### Documentation to Gather

• Device FDA clearance documentation: Clearance letter or 510(k) summary from the FDA database identifying the device, its cleared indication, and the cleared use parameters.
• Facility attestation: Letter from the treating facility confirming the device used and that it was used consistent with its FDA-cleared indication.
• Billing code verification: Confirm the CPT code submitted matches BCBS's coverage policy for TMS under the cleared indication.
• Diagnosis and medical-necessity documentation: Even if the primary denial basis is regulatory, BCBS may require clinical justification as well.
• Prescriber letter: Addresses the regulatory basis and clinical necessity.

### Criteria-Mapping Structure

Copy the exact BCBS policy language on FDA-approval requirements. Respond to each element with a specific document citation. For the clearance element, provide the FDA database record number and a printed copy. Reviewers who see organized, document-cited responses resolve these denials faster.